Q2 revenue and profit surge; court ends Rs 317.37 crore tax recovery exposure

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

MOREPENLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.6%Reaction day

₹126.51

prior close

₹132.31

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.7%+2.9% vs market

Pharmaceuticals peers, median of 173sector+2.0%+2.6% vs sector

On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 2.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.5

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.6+1.7+2.9+2.0+2.6

Next day

-0.7+1.8-2.5+2.6-3.4

-5.7+2.5-8.2+2.7-8.4

-10.4pendingpending+2.0-12.4

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated revenue for the quarter ended 30 September 2026 rose 81.4% year on year to Rs 74,650.19 lakh. Profit after minority interest rose 117.5% to Rs 8,889.47 lakh. For the half year, revenue rose 57.3% to Rs 131,663 lakh and profit rose 181.4% to Rs 14,529.41 lakh. Operating cash flow was Rs 12,748.11 lakh. The Himachal Pradesh High Court quashed a Rs 117.94 crore tax recovery notice, ending a Rs 317.37 crore contingent liability.

Likely market impact

Strong sales, profit and cash flow growth, plus removal of a large tax liability, are positive for shareholders and may support the stock.